ABCG2 and cancer: In turn, afatinib may enhance the efficacy of YM155 in breast cancer cells by inhibiting YM155 efflux; indeed, afatinib has been shown to inhibit the ABCB1 drug efflux transporter in ovarian cancer87 and the ABCG2 drug efflux transporter in other cancer types88.